文献速递膀胱癌与上尿路尿路上皮癌

中危非肌层浸润性膀胱癌随访策略的细化探索

Towards Defining Follow-up Strategies for Patients with Primary Intermediate-risk Non-muscle-invasive Bladder Cancer.
PubMed 文献 · Eur Urol Oncol · 2025-05-21

该回顾性分析纳入2086例按WHO 1973分级的中危非肌层浸润性膀胱癌患者,多因素Cox回归显示多灶性和肿瘤≥3 cm与首次复发风险显著相关,据此分为IR-High和IR-Low组。IR-High组3年无复发生存率51%(95%CI 48-54%),显著低于IR-Low组的68%(95%CI 65-71%);5年无进展生存率96%,两组无显著差异。结论提示随访应依据复发风险而非分级进行分层。

要点

  • 多灶性和肿瘤≥3 cm是中危NMIBC首次复发的显著预测因素。
  • IR-High组3年无复发生存率51%,显著低于IR-Low组的68%。
  • 两组5年无进展生存率96%,进展风险低且无显著差异。

核心结论

  • 中危NMIBC随访应依据肿瘤大小和灶数评估复发风险,而非仅依据分级。
  • 对复发风险较高的中危患者应采用更严格的随访方案。

研究设计与样本

  • 回顾性分析2086例按WHO 1973分级的中危NMIBC患者。
  • 采用多因素Cox回归识别复发预测因素,并据此二分为IR-High与IR-Low组。
  • IR-Low定义为单发且肿瘤<3 cm,共1087例。

主要发现

  • 多灶性和肿瘤≥3 cm与首次复发风险显著升高相关。
  • IR-High组3年无复发生存率51%(95%CI 48-54%),IR-Low组68%(95%CI 65-71%),差异显著。
  • 5年无进展生存率96%,IR-High与IR-Low组间无显著差异。

关键数值与推荐

  • IR-High定义:多灶性或肿瘤≥3 cm。
  • IR-Low定义:单发且肿瘤<3 cm(n=1087)。
  • 3年RFS:IR-High 51%(95%CI 48-54%),IR-Low 68%(95%CI 65-71%)。
  • 5年PFS率96%。

临床怎么用

  • 随访中应结合肿瘤大小和灶数评估中危NMIBC复发风险。
  • 对多灶性或肿瘤≥3 cm的中危患者可考虑更严格的随访频率。
  • 进展风险低,随访策略可侧重复发监测。

局限性

  • 为回顾性分析,可能存在选择偏倚。
  • 采用WHO 1973分级方案,与当前分级体系存在差异。
  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: The current European Association of Urology (EAU) guidelines on non-muscle-invasive bladder cancer (NMIBC) categorize patients into four risk groups. In 2024, a specific follow-up schedule was introduced for intermediate-risk (IR) disease. However, recommendations are based on expert opinion and restricted to patients with IR-NMIBC who have primary low-grade or high-grade/grade 2 disease. Our aim was to identify a subgroup of patients with IR-NMIBC who may require more stringent follow-up. METHODS: We conducted a retrospective analysis of 2086 patients with IR-NMIBC classified according to the World Health Organization 1973 grading scheme. Multivariable Cox-regression models were fitted to identify predictors of recurrence, which were then used to dichotomize groups with low risk of recurrence (IR-Low) versus high risk of recurrence (IR-High). Kaplan-Meier curves were plotted to estimate recurrence-free survival (RFS) and progression-free survival (PFS). Smoothed hazard estimates of first recurrence were plotted by risk group. KEY FINDINGS AND LIMITATIONS: Multifocality and tumor size ≥3 cm were significantly associated with higher risk of first recurrence and were used to define the IR-High and IR-Low (unifocal, size <3 cm; n = 1087) groups. The 3-yr RFS rate was significantly worse for the IR-High group (51%, 95% confidence interval [CI] 48-54%) than for IR-Low (68%, 95% CI 65-71%). The risk of progression was low (5-yr PFS rate 96%) with no significant difference between the IR-High and IR-Low groups. CONCLUSIONS AND CLINICAL IMPLICATIONS: During IR-NMIBC follow-up for recurrence, tumor size and focality should be considered rather than grade. If the primary objective is to ensure prompt detection of recurrence, follow-up schedules should be tailored according to the risk of recurrence, with more stringent protocols for patients with IR-NMIBC at higher risk of recurrence.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Contieri R, Martini A, Beijert IJ, et al. Towards Defining Follow-up Strategies for Patients with Primary Intermediate-risk Non-muscle-invasive Bladder Cancer. Eur Urol Oncol. 2025. PMID: 40399193. doi:10.1016/j.euo.2025.04.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。